Suzhou Molarray Co Ltd, a high-tech enterprise engaged in molecular diagnosis and gene detection technology in SIP’s BioBAY, has expanded its presence with subsidiaries in both China and overseas.

As one of the earliest Chinese companies to develop and mass-produce high-throughput qPCR (quantitative PCR) instruments, Molarray has created a product portfolio encompassing over 40 devices for genetic testing, standardized cell preparation, continuous monitoring of tumor cells and cell therapy. These products are widely applied in clinical in-vitro diagnosis, public health services, customs inspection, agriculture and food safety guarantee.

The company now holds more than 160 patents and 40 software copyrights granted by domestic and overseas organizations. It has obtained eight Class III medical device licenses from National Medical Products Administration of China and 27 CE certifications from the European Union.

Since its establishment in SIP in 2010, Molarray has secured fast growth with strong local support. In 2023, it put into operation its headquarters in the area, gaining stronger capabilities for R&D, mass production and international cooperation.

While strengthening its domestic market presence, the company is accelerating its global outreach. It has established marketing channels in Southeast Asia, the Middle East, Africa and Europe, striving to bring its precision medical solutions worldwide.

October 22, 2025